Skip to content

Manual Immediately Sequential Bilateral Cataract Surgery (M-ISBCS) vs Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS)

A Comparison of Patient Perceptions Undergoing Manual Immediately Sequential Bilateral Cataract Surgery (M-ISBCS) vs Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05480839
Enrollment
100
Registered
2022-07-29
Start date
2022-06-01
Completion date
2022-08-31
Last updated
2022-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Anesthesia vs Standard Anesthesia, Immediately Sequential Bilateral Cataract Surgery, MCS vs ReLACS, Pain Perception Postoperative

Brief summary

The focus of this study is to assess the differences in patient perceptions of pain undergoing cataract surgery by using the Refractive Laser-Assisted Cataract Surgery (ReLACS) technique compared to the standard Manual Cataract Surgery (MCS) technique using an immediately sequential bilateral approach. This study also aims to further explore difference in patients' perceptions of pain depending on timing of neurolept anesthesia in the ReLACS technique. The importance of this study is appreciated patient perception of pain during ReLACS, which is an emerging technique for cataract surgery and has been sparsely reported on to date. This investigation will include the analysis of various surgical, ocular, medical, and psychosocial metrics of patients undergoing both ReLACS and MCS at Uptown Eye specialist.

Interventions

PROCEDUREM-IBCS

Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant

PROCEDUREReLA-IBCS Early

Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia

PROCEDUREReLA-ISBCS

Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia

Sponsors

Uptown Eye Specialists
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Patients undergoing uncomplicated cataract surgery with either surgical technique (M-ISBCS or ReLA-ISBCS) * Patients who require surgery in both eyes by the same surgeon * Able to understand English and complete a pain assessment (NRS)

Exclusion criteria

* Deafness or communication disorder, known Dementia, Severe COPD/Asthma (severe lung disorder), Severe OSA, Psychiatric or Anxiety conditions, involuntary movement disorders, allergy to the anesthesia, any conditions requiring intraoperative iris manipulation, any prior ocular surgery * Pre-existing chronic eye pain or uveitis, or complicated cataracts (dislocation, zonulopathy) * Pre-existing uncontrolled glaucoma/high IOP * Intraoperative complications or non-routine cataracts (eg. Sutures, excessive time of surgery) * Any patient who requires Deep Sedation (Propofol), GA or preOP Ativan * Patients under 40, severe obesity (BMI \>35) * Chronic pain/narcotics/recreational or medical marijuana

Design outcomes

Primary

MeasureTime frameDescription
Pain Perception between Manual Immediately Sequential Bilateral Cataract Surgery (M-ISBCS) and Refractive Laser-Assisted Immediately Sequential Cataract Surgery (ReLA-ISCS)1 yearPain perceptions of patients undergoing M-IBCS vs ReLA-ISBCS will be measured using the Numerical Rating Scale (NRS) with pain ratings from 0 to 10.

Secondary

MeasureTime frameDescription
Effects of Early vs Standard administration of topical neurolept anesthesia on pain perception1 YearPain perceptions of patients undergoing ReLA-ISBCS Early vs ReLA-ISBCS Standard will be measured using the Numerical Rating Scale (NRS) with pain ratings from 0 to 10.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026